New York | On his final earnings call as chief executive of gene sequencing company Illumina, Francis deSouza did his best to stay positive.

A contentious $US8 billion ($12.6 billion) takeover of cancer screening business Grail had prompted a campaign by activist investor Carl Icahn, fights with competition authorities on both sides of the Atlantic, and criticism from Grail’s founding directors.